BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There is a need for in vivo systems that allow for mechanistic drug resistance studies and (combinatorial) treatment optimization. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemper, Kristel, Krijgsman, Oscar, Kong, Xiangjun, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, van der Velden, Daphne L., Bleijerveld, Onno B., Kuilman, Thomas, Kluin, Roel J.C., Sun, Chong, Voest, Emile E., Ju, Young Seok, Schumacher, Ton N.M., Altelaar, A.F. Maarten, McDermott, Ultan, Adams, David J., Blank, Christian U., Haanen, John B., Peeper, Daniel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2016
Materias:
Resource
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929150/
https://www.ncbi.nlm.nih.gov/pubmed/27320919
http://dx.doi.org/10.1016/j.celrep.2016.05.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929150/
https://www.ncbi.nlm.nih.gov/pubmed/27320919
http://dx.doi.org/10.1016/j.celrep.2016.05.064

Ejemplares similares